BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodríguez-Pintó I, Espinosa G, Cervera R. Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep 2015;17:482. [PMID: 25604575 DOI: 10.1007/s11926-014-0482-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Previtali G, Seghezzi M, Moioli V, Sonzogni A, Cerutti L, Marozzi R, Ravasio R, Gianatti A, Guerra G, Alessio MG. The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome? Thromb Res 2020;194:192-4. [PMID: 32788116 DOI: 10.1016/j.thromres.2020.06.042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
2 Silver RM. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol 2018;42:26-32. [PMID: 29179957 DOI: 10.1053/j.semperi.2017.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Saraiva SDS, Custódio IF, Mazetto BDM, Collela MP, de Paula EV, Appenzeller S, Annichino-bizzachi J, Orsi FA. Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thrombosis Research 2015;136:1174-8. [DOI: 10.1016/j.thromres.2015.10.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
4 Annous Y, Manning S, Khoujah D. Ferritin, fever, and frequent visits: Hyperferritinemic syndromes in the emergency department. Am J Emerg Med 2021;48:249-54. [PMID: 34000525 DOI: 10.1016/j.ajem.2021.04.088] [Reference Citation Analysis]
5 de Holanda MI, Pôrto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol 2017;36:2859-67. [PMID: 28905254 DOI: 10.1007/s10067-017-3823-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
6 Bienaimé F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int 2017;91:34-44. [PMID: 27555120 DOI: 10.1016/j.kint.2016.06.026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
7 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
8 Piedrafita A, Ribes D, Cointault O, Chauveau D, Faguer S, Huart A. Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice. Transfus Apher Sci 2020;59:102990. [PMID: 33272850 DOI: 10.1016/j.transci.2020.102990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
10 Rovere-Querini P, Canti V, Erra R, Bianchi E, Slaviero G, D'Angelo A, Rosa S, Candiani M, Castiglioni MT. Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore) 2018;97:e12584. [PMID: 30290624 DOI: 10.1097/MD.0000000000012584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Cervera R, Rodríguez-pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. Journal of Autoimmunity 2018;92:1-11. [DOI: 10.1016/j.jaut.2018.05.007] [Cited by in Crossref: 79] [Cited by in F6Publishing: 55] [Article Influence: 19.8] [Reference Citation Analysis]
12 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
13 Rodriguez-pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: The current management approach. Best Practice & Research Clinical Rheumatology 2016;30:239-49. [DOI: 10.1016/j.berh.2016.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
14 Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Review of Hematology 2017;10:365-74. [DOI: 10.1080/17474086.2017.1300522] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
15 Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol 2016;28:218-27. [PMID: 26927441 DOI: 10.1097/BOR.0000000000000269] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
16 Guerra OJL, Rodríguez RSG, Camacho WJM, Ortiz JEP, Camacho MAM. HEMOLYTIC UREMIC SYNDROME ASSOCIATED WITH STREPTOCOCCUS PNEUMONIAE IN PEDIATRICS: A CASE SERIES. Rev Paul Pediatr 2020;38:e2018065. [PMID: 31778402 DOI: 10.1590/1984-0462/2020/38/2018065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kazzaz NM, Wilson AM, Kado R, Barnes GD, Knight JS. A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia. Arthritis Care Res (Hoboken) 2017;69:1253-9. [PMID: 27992694 DOI: 10.1002/acr.23168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vreede AP, Bockenstedt PL, McCune WJ, Knight JS. Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol 2019;31:231-40. [PMID: 30747734 DOI: 10.1097/BOR.0000000000000595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
19 Özgür G, Beyan C. Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. Transfus Apher Sci 2018;57:13-5. [PMID: 29478799 DOI: 10.1016/j.transci.2018.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Bernardoff I, Picq A, Loiseau P, Foret T, Dufrost V, Moulinet T, Unlu O, Erkan D, Wahl D, Zuily S. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev 2021;:102913. [PMID: 34371159 DOI: 10.1016/j.autrev.2021.102913] [Reference Citation Analysis]
21 El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association? Clin Med Insights Arthritis Musculoskelet Disord 2020;13:1179544120978667. [PMID: 33328777 DOI: 10.1177/1179544120978667] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
22 Plummer MP, Young AMH, O'Leary R, Damian MS, Lavinio A. Probable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection. Neurocrit Care 2018;28:127-32. [PMID: 28357636 DOI: 10.1007/s12028-017-0392-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Sheludchenko VM, Kozlovskaya NL, Smirnova TV, Krasnolutskaya EI. [Ophthalmic aspects of vascular and functional changes in malignant arterial hypertension of renal origin]. Vestn Oftalmol 2020;136:324-32. [PMID: 32880158 DOI: 10.17116/oftalma2020136042324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1719-32. [PMID: 31694864 DOI: 10.2215/CJN.05830519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]